EGFR and non-small cell lung carcinoma: Adjuvant osimertinib has been recently demonstrated in the phase III randomized trial named ADAURA to significantly improve disease-free survival of patients with resected EGFR-mutated stage IB-IIIA NSCLC, compared with a placebo.